Companion Diagnostic Market

The global companion diagnostics (CDx) market sits at the center of the precision medicine ecosystem, evolving from niche oncology tools into a strategic pillar for targeted therapy development and clinical decision-making. Market dynamics are shaped by a strong push pull interaction between powerful growth drivers, structural restraints, and emerging technology and therapeutic-area opportunities.

On the demand side, rising cancer and chronic disease prevalence, together with the growing adoption of targeted therapies and precision medicine, is rapidly increasing the clinical need for biomarker-based tests that can identify “right patient right drug right dose” combinations. At the same time, rapid technological advances in NGS, PCR, automated and digital platforms, AI/ML analytics, and liquid biopsy are expanding the range, speed, and sensitivity of CDx solutions, while closer drug diagnostic co-development and increasing regulatory approvals are embedding CDx directly into therapeutic labels and clinical pathways.

Counterbalancing these growth forces are substantial restraints that continue to limit the scale and equity of deployment. CDx development and validation remain capital-intensive and high risk, especially for multi-gene NGS assays and niche indications, which narrows participation to well-capitalized players. Regulatory complexity and varied approval pathways across the U.S., Europe, Japan, and emerging markets add time, cost, and uncertainty, as sponsors must navigate different evidentiary standards and device classifications while aligning with drug approval timelines.

Even after approval, limited and fragmented reimbursement, uneven access to advanced testing infrastructure, and low awareness among payers, clinicians, and patients frequently create a gap between theoretical availability and real-world utilization, particularly outside major academic centers and in low- and middle-income countries. Despite these frictions, the opportunity landscape is broadening. Expansion beyond oncology into cardiovascular, metabolic, autoimmune, infectious, and rare diseases promises to multiply the addressable patient pool as robust biomarkers and targeted agents emerge in these areas.

The rising prevalence of cancer and chronic diseases significantly drives the Companion Diagnostics Market by heightening demand for precision medicine tools that identify patients suitable for targeted therapies, optimizing treatment outcomes and minimizing ineffective interventions. In 2022, approximately 20 million new cancer cases occurred worldwide, with projections estimating 35.3 million by 2050 a 76.6% increase particularly sharp in low human development index (HDI) countries at 142%, underscoring the urgent need for biomarker-driven diagnostics. 

 
Chronic conditions exacerbate this, as nearly three-quarters of the global population is expected to live with at least one by 2025, including 76.4% of U.S. adults in 2023 facing issues like hypertension (34.5%), high cholesterol (35.3%), and diabetes (12.1%), which fuel demands for tests in oncology, cardiovascular, and neurological disorders. For instance, HER2 testing in breast cancer, affecting millions annually, pairs with trastuzumab to boost survival rates, while PD-L1 assays like 22C3 guide pembrolizumab use in non-small cell lung cancer, matching therapies to tumor profiles for up to 30-40% response improvements in eligible patients.

Increasing drug-diagnostic co-development and regulatory approvals propel the Companion Diagnostics Market by synchronizing biomarker tests with targeted therapies, ensuring timely patient access to precision treatments through streamlined parallel pathways. By 2025, co-development has become essential for oncology, immunology, and rare diseases, with structured workflows from biomarker identification to integrated clinical trials aligning timelines for pivotal approvals.
 
The FDA lists over 44 approved companion diagnostics by 2020, surging to more than 35 additional approvals between 2011 and recent years, predominantly for hematological and oncological drugs via platforms like IHC, NGS, and PCR, with most requiring Premarket Approval (PMA) as high-risk devices. For example, in Q1 2025, the FDA approved the Thera screen KRAS RGQ PCR Kit (QIAGEN) as a companion diagnostic for colorectal cancer patients with KRAS G12C mutations eligible for sotorasib, enabling precise stratification amid two such approvals that quarter.

North America: Expanding cancer survivors

North America leads in the Companion Diagnostics Market Size, accounting for over 0.04% of the global revenue in 2024, the U.S. it is estimated that over 2 million new cancer cases and more than 618,000 deaths, with a growing population of 18.6 million cancer survivors projected to reach 22.4 million by 2035. This epidemiological surge drives demand for personalized medicine, in which CDx play a central role in matching patients with specific targeted therapies effectively expanding the CDx market. Moreover, the enhanced FDA regulatory framework contributes significantly to market growth.

Since 2014, the FDA has issued multiple clear regulatory guidelines (e.g., “In Vitro Companion Diagnostic Devices”) to support early and effective co-development of therapeutics and companion diagnostics. In 2023–2024 alone, the FDA authorized 11 new companion diagnostic claims and expanded nine existing ones associated with oncology IVD devices. This enhanced clarity enables smoother regulatory pathways and faster time-to-market for CDx products, significantly stimulating innovation and investment in the sector.

Europe: Expanding clinical evidence

In Europe, the growth of the companion diagnostics (CDx) market in Europe is being driven by a confluence of regulatory advancements, expanding clinical evidence, public health imperatives, and rising disease burdens—all underpinned by authoritative data from EU institutions and the WHO. The introduction and implementation of the In Vitro Diagnostic Regulation (IVDR, EU 2017/746), which became fully applicable in May 2022, represent a significant turning point.

This regulation imposes stricter performance evaluation, clinical evidence, and transparency requirements for high-risk IVDs, including CDx. Under IVDR, notified bodies must now engage in formal consultations with the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) on companion diagnostics, and the EMA has established a dedicated CHMP CDx Expert Group to support these reviews, helping accelerate regulatory alignment between diagnostics and therapies.

Asia Pacific: Rapidly clinical evidence

Asia Pacific, the growth of the Companion Diagnostics (CDx) market in the Asia Pacific region is propelled by a convergence of rapidly rising cancer incidence, maturing regulatory frameworks, expanding government screening programs, and increasing reimbursement support. According to GLOBOCAN 2022, Asia recorded nearly 9.83 million new cancer cases and 5.46 million deaths, accounting for roughly 50% of global cancer incidence and 58% of cancer deaths.

Within individual markets, the burden is stark: China reported approximately 4.82 million cases in 2022, India logged 1.41 million cases with almost 917,000 deaths, and Japan saw over 1 million cases that year—all underscoring an urgent demand for precision medicine tools like CDx that enable targeted therapy and improved outcomeslutide.

Many global, regional, and local vendors characterize the Companion Diagnostics Market. The market is highly competitive, with all the players competing to gain market share. Intense competition, rapid advances in technology, frequent changes in government policies, and environmental regulations are key factors that confront market growth.
 
The vendors compete based on cost, product quality, reliability, and government regulations. Vendors must provide cost-efficient, high-quality products to survive and succeed in an intensely competitive market.The major players in the market Include Qiagen, Bio-Techne, BioMérieux, Thermo Fisher Scientific Inc., Illumina, Inc., Agilent Technologies, Inc., F. Hoffmann-la Roche Ltd, strategic market developments and decisions to improve operational effectiveness.